Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes

Area of Science:

• Genetics
• Molecular Biology
• Neurology

Background:

• Cyclin-dependent kinase-like 5 (CDKL5) gene mutations are linked to early-onset epilepsy and treatment-resistant seizures.
• Rett syndrome and Angelman syndrome are neurodevelopmental disorders with overlapping clinical features.
• Understanding CDKL5 mutations is crucial for diagnosing and managing these complex conditions.

Purpose of the Study:

• To identify novel CDKL5 mutations in patients with Rett syndrome, Angelman syndrome, and idiopathic autism.
• To correlate specific CDKL5 mutations with clinical phenotypes, including seizure severity and developmental milestones.
• To expand the known mutational repertoire of the CDKL5 gene.

Main Methods:

• Screening of 92 patients with Rett syndrome, 17 with Angelman syndrome, and 6 with idiopathic autism for CDKL5 mutations and exon deletions.
• Utilizing multiplex ligation-dependent probe amplification (MLPA) for mutation detection.
• RNA characterization to determine the impact of identified mutations on transcript integrity.

Main Results:

• Seven novel CDKL5 mutations were identified: six in the Rett syndrome cohort and one in an Angelman syndrome patient.
• A mild clinical presentation was associated with an exon 11 insertion (c.903_904 dupGA), while severe phenotypes correlated with de novo missense changes (c.215 T > C, c.380A > G) and truncating mutations.
• RNA analysis confirmed aberrant transcripts for missense and truncating mutations, suggesting altered protein function over haploinsufficiency.

Conclusions:

• The study expands the known spectrum of CDKL5 mutations, particularly in patients with phenotypes overlapping Rett syndrome.
• Altered CDKL5 protein function, rather than simple haploinsufficiency, appears to contribute to a more severe clinical presentation.
• Genetic screening in broader patient populations is essential for comprehensive CDKL5 mutation discovery.